Biomea Fusion Inc
BMEA1.590USD
+0.020+1.27%
交易中 （美東）報價延遲15分鐘
59.74M總市值
虧損本益比TTM
關於 Biomea Fusion Inc 公司
Biomea Fusion, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於發現和開發口服共價小分子，用於治療患有代謝疾病和基因定義的癌症的患者。共價小分子是一種合成化合物，可與其靶蛋白形成永久鍵。該公司正在利用其專有的 FUSION 系統發現、設計和開發一系列共價結合小分子藥物，旨在最大限度地爲患者帶來臨牀益處。其主要候選產品 BMF-219 旨在成爲一種口服、強效且選擇性的腦膜炎共價抑制劑，由其 FUSION 系統構建而成。該公司正在開發 BMF-219 用於治療腦膜炎調節或依賴性疾病，例如 1 型和 2 型糖尿病以及液體和實體腫瘤的亞型。其第二個開發候選產品 BMF-500 是一種 FMS 樣酪氨酸激酶 3 (FLT3) 激活突變的共價抑制劑。
公司簡介
公司代碼BMEA
公司名稱Biomea Fusion Inc
上市日期Apr 16, 2021
CEODr. Michael J.M. (Mick) Hitchcock, Ph.D.
員工數量106
證券類型Ordinary Share
年結日Apr 16
公司地址1599 Industrial Road
城市SAN CARLOS
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94070
電話16509809099
網址https://www.biomeafusion.com/
公司代碼BMEA
上市日期Apr 16, 2021
CEODr. Michael J.M. (Mick) Hitchcock, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Rainer M. (Ramses) Erdtmann
Mr. Rainer M. (Ramses) Erdtmann
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
2.53M
--
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Lead Independent Director
Lead Independent Director
200.00
--
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
--
--
Dr. Juan Pablo Fras
Dr. Juan Pablo Fras
Chief Medical Officer, Head of Diabetes
Chief Medical Officer, Head of Diabetes
--
--
Dr. Elizabeth Faust, Ph.D.
Dr. Elizabeth Faust, Ph.D.
Independent Director
Independent Director
--
--
Ms. Sumita Ray, J.D.
Ms. Sumita Ray, J.D.
Independent Director
Independent Director
--
--
,
,
Senior Director, Investor Relations and Corporate Development
Senior Director, Investor Relations and Corporate Development
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Rainer M. (Ramses) Erdtmann
Mr. Rainer M. (Ramses) Erdtmann
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
President, Co-Founder, Principal Financial Officer, Chief Operating Officer, Director
2.53M
--
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Lead Independent Director
Lead Independent Director
200.00
--
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Dr. Michael J.M. (Mick) Hitchcock, Ph.D.
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
--
--
Dr. Juan Pablo Fras
Dr. Juan Pablo Fras
Chief Medical Officer, Head of Diabetes
Chief Medical Officer, Head of Diabetes
--
--
Dr. Elizabeth Faust, Ph.D.
Dr. Elizabeth Faust, Ph.D.
Independent Director
Independent Director
--
--
Ms. Sumita Ray, J.D.
Ms. Sumita Ray, J.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 6月27日 週五
更新時間: 6月27日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
9.53%
Heights Capital Management, Inc.
7.80%
Cormorant Asset Management, LP
6.26%
Butler (Thomas Andrew)
5.22%
Erdtmann (Rainer M)
4.44%
Other
66.74%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
9.53%
Heights Capital Management, Inc.
7.80%
Cormorant Asset Management, LP
6.26%
Butler (Thomas Andrew)
5.22%
Erdtmann (Rainer M)
4.44%
Other
66.74%
股東類型
持股股東
佔比
Investment Advisor
25.05%
Hedge Fund
11.10%
Individual Investor
9.95%
Investment Advisor/Hedge Fund
7.02%
Research Firm
1.11%
Bank and Trust
0.31%
Family Office
0.10%
Pension Fund
0.03%
Other
45.33%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
269
31.12M
54.57%
-2.04M
2025Q1
286
30.27M
56.89%
-6.92M
2024Q4
291
32.11M
88.62%
-5.43M
2024Q3
283
32.46M
89.61%
-9.72M
2024Q2
276
32.63M
90.57%
-17.02M
2024Q1
262
40.47M
112.52%
-6.23M
2023Q4
249
37.13M
103.84%
-10.53M
2023Q3
227
38.85M
108.96%
-7.82M
2023Q2
225
38.32M
108.02%
-4.44M
2023Q1
192
32.77M
97.40%
+4.19M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
5.44M
9.53%
--
--
Mar 31, 2025
Heights Capital Management, Inc.
4.45M
7.8%
+4.45M
--
Jun 17, 2025
Cormorant Asset Management, LP
3.57M
6.26%
--
--
Mar 31, 2025
Butler (Thomas Andrew)
2.97M
5.22%
--
--
Mar 31, 2025
Erdtmann (Rainer M)
2.53M
4.44%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.96M
3.44%
-43.41K
-2.16%
Mar 31, 2025
The Vanguard Group, Inc.
1.38M
2.42%
-23.05K
-1.65%
Mar 31, 2025
Two Sigma Investments, LP
963.36K
1.69%
-56.07K
-5.50%
Mar 31, 2025
Aisling Capital Management LP
798.76K
1.4%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
625.95K
1.1%
+21.81K
+3.61%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Micro-Cap ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Morningstar Small-Cap ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
查看更多
ProShares Ultra Nasdaq Biotechnology
佔比0.01%
iShares Micro-Cap ETF
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0.01%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
iShares Morningstar Small-Cap ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
